Guardant Health, Inc. GH
Set alert
At close · Nov 2
After hours · Nov 2, 4:48 PM ET
- YTD
- +67.15%
- 1 year
- +83.54%
- Open
- 179.50
- Prev close
- 178.80
- Mkt cap
- 22.91B
- Vol
- 2.39M
- Avg vol
- 1.89M
- EPS
- -3.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 167.94
- High
- 180.05
- Forward P/E
- -450.27
- Beta
- 1.66
- Short ratio
- 6.12
- Inst. own
- 103.19%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 169.71
- 200-d avg
- 130.50
- 1y target
- 202.24
1Y chart
Events in this range
- Feb 19, 2026Earnings: -1; estimate -0.76677; surprise -30.42%
- May 7, 2026Earnings: -0.85; estimate -0.806; surprise -5.46%
- Jul 30, 2026Earnings: -0.9; estimate -0.76183; surprise -18.14%
- Sep 9, 2026Rating: UBS · Buy → Buy
- Oct 1, 2026Rating: Guggenheim · Buy → Buy
- Oct 7, 2026Rating: Barclays · Overweight → Overweight
- Oct 13, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 23, 2026Rating: Roth Capital · — → Buy
- Oct 27, 2026Rating: BTIG · Buy → Buy
Signals (43)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 5, 2026 | 4 weeks ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| RSI: Overbought | May 20, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Buy Signal | May 1, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 19, 2026 | 7 months ago |
| RSI: Oversold | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Feb 19, 2026 | 8 months ago |
| SMA: Bullish | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Feb 11, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| RSI: Overbought | Jan 22, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 10 months ago |
| RSI: Overbought | Jan 6, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| RSI: Overbought | Nov 19, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| RSI: Overbought | Nov 17, 2025 | 11 months ago |
Key statistics
- Market cap
- 22.91B
- Enterprise value
- 24.64B
- Trailing P/E
- 0.00
- Forward P/E
- -450.27
- PEG ratio
- 0.00
- Price / sales
- 19.37
- Price / book
- 0.00
- EPS (TTM)
- -3.50
- Beta
- 1.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -38.33%
- Revenue (TTM)
- 1.18B
- Revenue growth
- 44.30%
- Free cash flow
- 26.61M
- Total cash
- 1.05B
- Total debt
- 1.70B
- Return on equity
- 0.00%
- Shares outstanding
- 134.20M
- Short % of float
- 9.06%
- 50-day average
- 169.71
- 200-day average
- 130.50
Analyst view
Consensus: strong buy
- Target (low)
- 105.00
- Target (mean)
- 202.24
- Target (high)
- 240.00
- Strong buy4
- Buy21
- Hold0
- Sell0
- Strong sell1
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.31444.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.75 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.76183 | -0.90 | -0.14 | -18.14% |
| May 7, 2026 | Mar 31, 2026 | -0.806 | -0.85 | -0.04 | -5.46% |
| Feb 19, 2026 | Dec 31, 2025 | -0.76677 | -1.00 | -0.23 | -30.42% |
| Oct 29, 2025 | Sep 30, 2025 | -0.78962 | -0.74 | +0.05 | +6.28% |
| Jul 30, 2025 | Jun 30, 2025 | -0.74051 | -0.80 | -0.06 | -8.03% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | BTIG | main | Buy | Buy |
| Oct 23, 2026 | Roth Capital | init | — | Buy |
| Oct 13, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 9, 2026 | UBS | main | Buy | Buy |
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- guardanthealth.com
News
- Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
- Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
- BTIG Maintains Buy on Guardant Health, Raises Price Target to $210
- This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More
- Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200
- Guardant Health, Inc. (NASDAQ:GH) Stock Has Average Price Target of $190.00
- Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Your note
Sign in to keep a note on GH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BELL MICHAEL BRIAN | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 30, 2026 | 51,816 |
| CHUDOVA DARYA | Chief Technology Officer | Sale | Sep 14, 2026 | 70,635 |
| EAGLE CRAIG | Officer | Conversion of Exercise of derivative security | Mar 31, 2026 | 72,001 |
| ELTOUKHY HELMY A | Chief Executive Officer | Stock Gift | Aug 25, 2026 | 0 |
| FREEMAN CHRIS | Officer | Conversion of Exercise of derivative security | Aug 9, 2026 | 65,374 |
| GADDE VIJAYA V. | Director | Conversion of Exercise of derivative security | Jun 16, 2026 | 28,517 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.68% | 7,622,935 | 1.30B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.85% | 6,514,952 | 1.11B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.29% | 5,755,857 | 982.70M | Jun 29, 2026 |
| FMR, LLC | 4.09% | 5,488,272 | 937.01M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.06% | 5,445,785 | 929.76M | Jun 29, 2026 |
| Invesco Ltd. | 3.30% | 4,429,755 | 756.29M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.98% | 3,999,645 | 682.86M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.15% | 2,888,524 | 493.16M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.33% | 1,778,489 | 303.64M | Jun 29, 2026 |
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 1.30% | 1,750,000 | 298.78M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 1.29% | 1,729,500 | 295.28M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.24% | 1,665,905 | 284.42M | Jun 29, 2026 |